Zynerba Pharmaceuticals : January 2022 Corporate Presentation

Corporate Overview

January 2022

Forward-Looking Statements

THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS, AMONG OTHER THINGS RELATE TO THE FUTURE OPERATIONS, OPPORTUNITIES OR FINANCIAL PERFORMANCE OF ZYNERBA PHARMACEUTICALS, INC. WE MAY, IN SOME CASES, USE TERMS SUCH AS "PREDICTS," "BELIEVES," "POTENTIAL," "PROPOSED," "CONTINUE," "ESTIMATES," "ANTICIPATES," "EXPECTS," "PLANS," "INTENDS," "MAY,"

"COULD," "MIGHT," "WILL," "SHOULD" OR OTHER WORDS THAT CONVEY UNCERTAINTY OF FUTURE EVENTS OR

OUTCOMES TO IDENTIFY THESE FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS ARE SUBJECT TO

NUMEROUS IMPORTANT FACTORS, RISKS AND UNCERTAINTIES THAT MAY CAUSE ACTUAL EVENTS OR RESULTS TO DIFFER MATERIALLY FROM THE COMPANY'S CURRENT EXPECTATIONS, INCLUDING THE FOLLOWING: THE COMPANY'S CASH AND CASH EQUIVALENTS MAY NOT BE SUFFICIENT TO SUPPORT ITS OPERATING PLAN FOR AS LONG AS ANTICIPATED; THE RESULTS, COST AND TIMING OF THE COMPANY'S CLINICAL DEVELOPMENT PROGRAMS, INCLUDING ANY DELAYS TO SUCH CLINICAL TRIALS RELATING TO ENROLLMENT OR SITE INITIATION; CLINICAL RESULTS FOR THE COMPANY'S PRODUCT CANDIDATES MAY NOT BE REPLICATED OR CONTINUE TO OCCUR IN THE COMPANY'S ONGOING OR PLANNED CLINICAL TRIALS IN FXS,

ASD OR 22Q, OR IN ANY ADDITIONAL TRIALS, AND MAY NOT OTHERWISE SUPPORT FURTHER DEVELOPMENT IN A SPECIFIED INDICATION OR AT ALL; THE COMPANY'S PLANNED RECONNECT TRIAL MAY NOT BE DETERMINED TO BE SUFFICIENT TO SUPPORT A SUBMISSION FOR REGULATORY APPROVAL, INCLUDING AN NDA OR MAA; ACTIONS OR ADVICE OF THE U.S. FOOD AND DRUG ADMINISTRATION AND FOREIGN REGULATORY AGENCIES MAY AFFECT THE DESIGN, INITIATION, TIMING, CONTINUATION AND/OR PROGRESS OF CLINICAL TRIALS OR RESULT IN THE NEED FOR ADDITIONAL CLINICAL TRIALS; THE COMPANY'S ABILITY TO OBTAIN AND MAINTAIN REGULATORY APPROVAL FOR ITS PRODUCT CANDIDATES, AND THE LABELING UNDER ANY SUCH APPROVAL; THE COMPANY'S EXPECTATIONS REGARDING ITS ABILITY TO OBTAIN AND ADEQUATELY MAINTAIN SUFFICIENT INTELLECTUAL PROPERTY PROTECTION FOR ITS PRODUCT CANDIDATES. THESE AND OTHER RISKS ARE DESCRIBED IN OUR FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, AVAILABLE AT WWW.SEC.GOV. ANY FORWARD-LOOKING STATEMENTS THAT THE COMPANY MAKES IN THIS PRESENTATION SPEAK ONLY AS OF THE DATE OF THIS PRESENTATION. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE FORWARD-LOOKING STATEMENTS WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, AFTER THE DATE OF THIS PRESENTATION.

© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their

respective owners.	2

Zynerba Pharmaceuticals (NASDAQ: ZYNE)

A Rare/Near-Rare Neuropsychiatric Company

• Deep pipeline targeting high unmet medical needs; translating into multi-billion dollar market opportunity with Zygel™ (Cannabidiol Gel)
• Two Phase 3 clinical development programs ongoing/planned
• • Confirmatory RECONNECT pivotal trial in Fragile X syndrome (FXS) initiated September 2021, with topline results expected 2H 2023
  • Plan to initiate pivotal Phase 3 program in autism spectrum disorder (ASD) 2H 2022
• Phase 2 study ongoing in 22q11.2 deletion syndrome (22q) with topline results expected mid-year 2022
• Experienced team with development and commercial expertise in transdermal delivery, orphan diseases, neurology, and psychiatry
• Cash runway expected to be sufficient to fund operations and capital requirements into 2H 2023

3

Deep Clinical Pipeline &

Near-term Milestones

Zygel

Cannabidiol Gel

Indication	Preclinical	Phase 1	Phase 2	Pivotal

Fragile X Syndrome (FXS)*

RECONNECT: Pivotal confirmatory trial initiated

Autism Spectrum Disorder (ASD)

BRIGHT: Topline data released

22q Deletion Syndrome (22q)**

INSPIRE: Ongoing

Expected Milestones

Topline results expected 2H 2023

Initiate Phase 3 program 2H

2022

Topline results expected mid-

year 2022

*Orphan Drug and Fast Track designation **Orphan Drug designation

4

Zygel (ZYN002) Cannabidiol Gel

Unique Neuropsych

Differentiated Transdermal Mechanism Indications

of Action

First & only patent-	Formulation	Cannabidiol	Potential utility in rare / near-
protected (2038),	delivers	modulates multiple	rare neuropsychiatric
permeation-enhanced,	Cannabidiol	receptors and	conditions
pharmaceutically-	through the	mediates numerous
produced cannabidiol gel	epidermis and into	pathways, including
	the circulatory	the endocannabinoid
	system	pathway

5